Can Amlodipine Be Prescribed for Raynaud's Phenomenon?
Yes, amlodipine can be prescribed for Raynaud's phenomenon, though it is not the first-line calcium channel blocker of choice—nifedipine is preferred based on the strongest guideline evidence.
First-Line Treatment: Nifedipine, Not Amlodipine
The 2025 EULAR guidelines for systemic sclerosis explicitly recommend dihydropyridine-type calcium channel blockers, specifically oral nifedipine, as first-line therapy for Raynaud's phenomenon 1. This recommendation is echoed by the 2023 Nature Reviews Rheumatology state-of-the-art review, which states that "Raynaud phenomenon and digital ulcers are treated with dihydropyridine calcium channel blockers (especially nifedipine)" 2.
Why Amlodipine Is a Reasonable Alternative
While nifedipine holds the strongest evidence base, amlodipine is a dihydropyridine calcium channel blocker in the same drug class and can be used when nifedipine is not tolerated or as an alternative option. Here's the supporting evidence:
Mechanism of action: Amlodipine works through the same vasodilatory mechanism as nifedipine, blocking calcium channels to promote peripheral vasodilation 3
Clinical evidence: A 2017 Cochrane review of calcium channel blockers for Raynaud's found that CCBs reduced attack frequency by approximately 2.93 attacks per week (moderate-quality evidence) and reduced severity scores, though effects were modest 4. While most data pertained to nifedipine, the review included other dihydropyridines
Direct comparison data: A 2014 head-to-head trial comparing amlodipine 10 mg/day with the PDE5 inhibitor udenafil in secondary Raynaud's showed that amlodipine significantly decreased the rate of Raynaud's attacks 5
Historical support: A 1998 review noted that "newer second-generation dihydropyridines such as amlodipine...appear to be effective in patients with RP and may be associated with fewer adverse effects" 6. A 2006 meta-analysis confirmed amlodipine showed "significant effects in single randomized controlled trials" 7
Practical Prescribing Algorithm
Step 1: Start with nifedipine (typically extended-release 30-60 mg daily) as per guideline recommendations 1, 2
Step 2: Switch to amlodipine if:
- Patient experiences intolerable side effects from nifedipine (headache, flushing, reflex tachycardia)
- Patient has contraindications to nifedipine
- Patient prefers once-daily dosing with potentially fewer vasodilatory side effects
Amlodipine dosing: Start at 5 mg daily, can increase to 10 mg daily based on response 3
Step 3: If inadequate response to calcium channel blockers, consider adding:
- PDE5 inhibitors (sildenafil, tadalafil) 1
- Intravenous iloprost for severe disease refractory to oral therapy 1, 2
Important Caveats
Side effect profile: Both nifedipine and amlodipine cause peripheral edema, headache, flushing, and dizziness through vasodilation 3. The FDA label notes edema occurs in 10.8% at 10 mg amlodipine doses 3. However, amlodipine's longer half-life may result in more sustained but potentially better-tolerated vasodilation compared to immediate-release nifedipine.
Hypotension risk: In patients with baseline hypotension or tendency toward low blood pressure, calcium channel blockers can be problematic. A 2020 review noted that despite blood pressure concerns, CCBs remain first-line treatment, but careful monitoring is essential 8. Consider starting at lower doses (amlodipine 2.5-5 mg) in these patients.
Primary vs. Secondary Raynaud's: The Cochrane review suggests that dihydropyridine CCBs may be more effective in primary Raynaud's than secondary Raynaud's 4, 9, though the difference was modest. For secondary Raynaud's associated with systemic sclerosis, the evidence base is stronger for nifedipine specifically 1.
Efficacy expectations: Set realistic expectations—CCBs provide modest benefit. The 2017 Cochrane review found CCBs reduced attack frequency by about 3 attacks per week and severity by 0.62 cm on a 10-cm scale, which may not be clinically meaningful for all patients 4.
No serious adverse events: Importantly, across all trials, no serious adverse events (death or hospitalization) were reported with CCB use for Raynaud's 4.